Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · October 08, 2024

Neoadjuvant Nivolumab vs Nivolumab Plus Ipilimumab for Early-Stage TNBC

Nature Medicine

 

Additional Info

Nature Medicine
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
Nat. Med. 2024 Sep 16;[EPub Ahead of Print], I Nederlof, OI Isaeva, M de Graaf, RCAM Gielen, NAM Bakker, AL Rolfes, H Garner, B Boeckx, JJH Traets, IAM Mandjes, M de Maaker, T van Brussel, M Chelushkin, E Champanhet, M Lopez-Yurda, K van de Vijver, JG van den Berg, I Hofland, N Klioueva, RM Mann, CE Loo, FH van Duijnhoven, V Skinner, S Luykx, E Kerver, E Kalashnikova, MGJ van Dongen, GS Sonke, SC Linn, CU Blank, KE de Visser, R Salgado, LFA Wessels, CA Drukker, TN Schumacher, HM Horlings, D Lambrechts, M Kok

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading